Cipla and BioQuiddity announce EU Commercial Partnership for Ready-to-Use Ropivacaine Infusion Product for Post-Surgical Pain Management
Jul 31, 2014
INDIA, MUMBAI, July 31 2014: Cipla Europe NV ("Cipla") and BioQuiddity Inc. announced today that they recently entered into a commercial collaboration, covering the territory of the European Union and certain other European countries, for BioQuiddity's Ready-to-Use Ropivacaine infusion pharmaceutical in regional anesthetic applications for post-surgical pain management. Cipla intends to launch the Ropivacaine infusion pharmaceutical under its own label into the German market late this year. The ready-to-use infusion systems are non-electric, ambulatory, and should enable seamless transition between sites of care.
"Cipla is an excellent strategic partner for BioQuiddity and our pre-filled ready-to-use post-surgical pain product candidates," said Joshua Kriesel President and CEO. "Cipla's strong commercial record puts them in an outstanding position to detail the Ropivacaine infusion pharmaceutical's safety, sterility, and ease of use value proposition objectives.
"We are thrilled to be BioQuiddity's European commercial partner for Ropivacaine", said Frank Pieters, CEO Cipla EU. "Cipla believes that this post-surgical pain product candidate presents a unique opportunity to provide an easy to use, well-tolerated, and efficient regional anesthesia system that could make savings for healthcare providers and patients."
About Cipla Limited
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2013-14 was 1.7 billion USD.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.
Cipla Europe NV is a 100% subsidiary of Cipla Limited.
About BioQuiddity
BioQuiddity is a privately held corporation located in San Francisco California. The Company is focused on addressing some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQuiddity's ultimate objective is to provide value to the healthcare community by playing a vital role in containing costs and improving quality via the Company's proprietary unit-dose infusion systems. The Company is ISO13485 certified. West Pharmaceutical Services, an existing strategic partner of BioQuiddity's, will be assembling the Ready-to-Use Ropivacaine Infusion Product.
Investors/Media:
Charlotte Chunawala
Corporate Communications
charlotte.chunawala@cipla.com
+91 7506257377
Jaisingh Balakrishnan
Corporate Communications
charlotte.chunawala@cipla.com
+91 9833836185